The Korea Times close
National
  • Politics
  • Diplomacy
  • Defense
  • Labor & Environment
  • Law & Crime
  • Health & Welfare
  • Embassy
  • Seoul & Provinces
  • Education
  • Foreign Communities
  • Obituaries
Biz & Tech
  • Auto
  • IT
  • Game
  • Manufacturing
  • Retail & Food
  • Energy
  • Construction
  • Airlines
Finance
  • Policies
  • Economy
  • Markets
  • Banks
  • Non-banks
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to the Editor
Lifestyle
  • Arts
  • Books
  • Travel & Cuisine
  • Trend
  • Fashion
  • Around Town
  • Fortune Telling
Entertainment
  • K-pop
  • K-dramas & Shows
  • Movies
  • Music
  • Performances
  • Asia Model Festival
Sports
  • Football
  • Golf
  • Baseball
  • Other Sports
World
  • Asia Pacific
  • Americas
  • Europe & Africa
  • SCMP
Video
  • On the Spot
  • Feature
  • News
Photos
  • Photo News
  • Darkroom
Community
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
World
  • Asia Pacific
  • Americas
  • Europe & Africa
  • SCMP
Mon, April 12, 2021 | 21:19
Europe & Africa
EU, UK regulators find possible link between AstraZeneca and rare blood clots
Posted : 2021-04-08 08:11
Updated : 2021-04-08 08:11
Mail
Print Preview
Font Size Up
Font Size Down
A member of the medical staff draws serum from an AstraZeneca vaccine container at a vaccination center in Bucharest, Romania, April 7. AP
A member of the medical staff draws serum from an AstraZeneca vaccine container at a vaccination center in Bucharest, Romania, April 7. AP

European and British medicine regulators said on Wednesday they had found possible links between AstraZeneca's coronavirus vaccine and reports of very rare cases of brain blood clots, in a setback for inoculation campaigns.

A British government advisory group said the vaccine should not be given to the under 30s where possible, though an official said this was "really out of the utmost caution, rather than because we have any serious safety concerns".

More than a dozen countries have suspended use of the vaccine, which has been given to tens of millions of people in Europe, after reports linking it to blood clotting in a few dozen recipients.

In its statement, the European Medicines Agency (EMA) said it was "reminding healthcare professionals and people receiving the vaccine to remain aware of the possibility of very rare cases of blood clots combined with low levels of blood platelets occurring within 2 weeks of vaccination".

"So far, most of the cases reported have occurred in women under 60 years of age within 2 weeks of vaccination," it added. "Based on the currently available evidence, specific risk factors have not been confirmed."

The EMA received reports of 169 cases of the rare brain blood clot by early April, after 34 million doses had been administered in the European Economic Area, according to Sabine Straus, chair of the EMA's safety committee.

In comparison, four women out of 10,000 would get a blood clot from taking oral contraception.

"We know that we are rolling out vaccines on a very large scale. We will see events occurring... Some of them by chance," Straus said.

EU health ministers were told in a letter from the EMA seen by Reuters that the announcement on the safety of the vaccine would have immediate implications for vaccination plans and require a coordinated response.

The chief executive of Britain's health regulator, June Raine, said the benefits of the vaccine outweighed the risks for the vast majority of people. She said those risks were more finely balanced for younger people - for whom the risks from coronavirus infection are, on average, lower.

Wei Shen Lim, COVID-19 Chair for Britain's advisory Joint Committee on Vaccines and Immunisation, said it was preferable for adults under 30 with no underlying health conditions to be offered another vaccine.

Ministers to meet

The letter to the EU health ministers was sent by the Portuguese presidency of the EU on Tuesday to invite them to an extraordinary virtual meeting on Wednesday, to be held immediately after the decision by the EU drugs regulator.

The AstraZeneca vaccine is sold at cost, for a few dollars a dose, and is by far the cheapest and most high-volume launched so far, and has none of the extreme refrigeration requirements of some other COVID-19 vaccines.

After extensive use in Britain and mainland Europe, it is set to be the mainstay of vaccination programmes in much of the developing world.

Experts say that, even if a causal link between the vaccine and blood clots is proved, the risks to the general population of getting a serious clot are vanishingly small compared to the risks from possible COVID-19 infection, which can also cause similar clots, or from many other widely used drugs such as the birth control pill.

"The risk of mortality from COVID is much greater than the risk of mortality from these rare side-effects," EMA's executive director Emer Cooke said on Wednesday.

AstraZeneca has said previously its studies have found no higher risk of blood clots in those vaccinated than in the general population.

But the shot has faced questions since late last year, when the drugmaker and Oxford University published data from an earlier trial with two different efficacy readings as a result of a dosing error.

AstraZeneca last month published early results of its U.S. late-stage clinical trial showing the shot was 79% effective, but then had to scramble to release more data after a rare rebuke from U.S. health officials, who said the data was outdated.

Scientists are exploring several possibilities that might explain the rare brain blood clots. One theory suggests the vaccine triggers an unusual antibody in some rare cases; other investigators are looking into a possible link with birth control pills.

But many experts say there is no definitive evidence, and that it is not clear whether or why AstraZeneca's vaccine would cause a problem not shared by other vaccines that target a similar part of the coronavirus.

While many countries have resumed using the shot, some have imposed age restrictions, with younger women perceived to be more vulnerable. (Reuters)


Signs show Korea has entered 4th wave of infections
Korea may be at the beginning of a fourth big wave of COVID-19 infections, according to health experts, with the daily caseload reaching its highest level in three months amid spor...
Korea to resume AstraZeneca jabs amid lingering safety woes
Korea's health authorities on Thursday said they will resume administering AstraZeneca vaccines one day after suspending the vaccination program for certain groups over its safety,...
PM orders full review of EMA's findings before resuming use of AstraZeneca vaccine
Prime Minister Chung Sye-kyun on Thursday ordered health authorities to thoroughly and swiftly review the latest findings by the European Medicines Agency (EMA) on the safety of As...
Korea suspends AstraZeneca vaccination programs due to concerns over blood clots
South Korea decided Wednesday to suspend a AstraZeneca COVID-19 vaccination program for people younger than 60 due to concerns related to blood clots. Set to start on Thursday, Ast...









 
LG
 
  • Korean FA-50 competes with Pakistan-China developed jet in Malaysia
  • New Seoul mayor seeks overhaul in quarantine, real estate policies
  • Korea to resume AstraZeneca injections except on people under 30
  • Survivors of xenophobia, hate crime captured in photos
  • Concerns growing over deepening social divide amid pandemic
  • North Korea's SLBM threat looms large
  • SK to pay $1.78 bil. to settle battery dispute with LG
  • Harry but no Meghan at pared-back funeral for Prince Philip
  • Cloud of uncertainty remains as countdown to Tokyo Olympics nears 100 days
  • LG, SK reach last-minute settlement in International Trade Commission battery dispute
  • From Rose to Baekhyun, K-pop group members also shine as solo acts From Rose to Baekhyun, K-pop group members also shine as solo acts
  • 'Nothing less than a giant': Rapper-actor DMX dies at 50 'Nothing less than a giant': Rapper-actor DMX dies at 50
  • BLACKPINK's Rose sets 2 Guinness World Records with solo release BLACKPINK's Rose sets 2 Guinness World Records with solo release
  • 'Way Back Home' follows rape survivor's path to healing from trauma 'Way Back Home' follows rape survivor's path to healing from trauma
  • Mamamoo to hold online concert on British streaming platform next month Mamamoo to hold online concert on British streaming platform next month
DARKROOM
  • Locust outbreak

    Locust outbreak

  • Death toll rises as protests continue in Myanmar

    Death toll rises as protests continue in Myanmar

  • Say 'NO' to racism (Part 2)

    Say 'NO' to racism (Part 2)

  • Say 'NO' to racism (Part 1)

    Say 'NO' to racism (Part 1)

  • Worst dust storm chokes Beijing

    Worst dust storm chokes Beijing

The Korea Times
CEO & Publisher : Oh Young-jin
Digital News Email : webmaster@koreatimes.co.kr
Tel : 02-724-2114
Online newspaper registration No : 서울,아52844
Date of registration : 2020.02.05
Masthead : The Korea Times
Copyright © koreatimes.co.kr. All rights reserved.
  • About Us
  • Introduction
  • History
  • Location
  • Media Kit
  • Contact Us
  • Products & Service
  • Subscribe
  • E-paper
  • Mobile Service
  • RSS Service
  • Content Sales
  • Policy
  • Privacy Statement
  • Terms of Service
  • 고충처리인
  • Youth Protection Policy
  • Code of Ethics
  • Copyright Policy
  • Family Site
  • Hankookilbo
  • Dongwha Group